Revolutionizing Brain Health with the First Scalable iPSC-Derived Microglia Cell

Voxel Therapeutics is pioneering the first scalable, clinically relevant human iPSC-derived microglia for research, drug discovery, and therapeutic applications.

Our vision is to create the foundation for microglia-based neurotherapeutics by combining advanced AI/ML-driven computational biology (Voxel Compute) with rational cell engineering. This will enable us to generate functional microglia at scale, optimized for both drug discovery and cell-based therapies.